Brief: Sellas Announces Positive Overall Survival In Cohort 3 From Phase 2 Trial Of Sls009 In R/R Aml

Sellas Life Sciences

08/04/2025 14:27

April 8 (Reuters) - Sellas Life Sciences Group Inc SLS.O:

SELLAS ANNOUNCES POSITIVE OVERALL SURVIVAL IN COHORT 3 FROM THE ONGOING PHASE 2 TRIAL OF SLS009 IN R/R AML

SELLAS LIFE SCIENCES GROUP INC: TRIAL CONTINUES WITH FULL DATA AND FDA REGULATORY PATH FEEDBACK EXPECTED IN 1H 2025

SELLAS LIFE SCIENCES GROUP INC:  OVERALL RESPONSE RATE (ORR) OF 67% ACHIEVED IN PATIENTS WITH AML-MRC

Source text: ID:nGNX7dS0Gz

Further company coverage: SLS.O

 ((Reuters.Briefs@thomsonreuters.com;))